Home > Insider Trading > Filing (0001209191-20-051615)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1438533	Retrophin Inc.	RTRX	Pharmaceutical Preparations (2834)	262383102

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1698262	E. William Rote	C/O Retrophin, Inc. 3721 Valley Centre Drive, Ste 200 San Diego CA 92130	Senior Vice President, R&D	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-09-18	3,000	$0.00	27,086	No	4	A	Direct
Common Stock	Disposition	2020-09-22	1,500	$18.59	25,586	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Footnotes

On May 9, 2019, the reporting person was granted performance restricted stock units (PRSUs) covering 6,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On September 18, 2020, a portion of the PRSUs vested upon the Issuer's confirmation that the first 280 patients in the sparsentan PROTECT Phase 3 Study had been enrolled.
Includes 592 shares of the Issuer's common stock acquired by the reporting person on May 31, 2020 pursuant to an employee stock purchase program.
The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligationthat occurred upon the vesting of performance restricted stock units.